Infectious Disease Diagnostics Market

The infectious disease diagnostics market is valued at an estimated USD 21.4 billion in 2023 and is projected to reach USD 31.5 billion by 2028 at a CAGR of 8.0% during the forecast period. Market growth is largely driven by the rising prevalence of infectious diseases and the increasing funding for R&D in disease diagnostics. The rising incidence of infectious diseases worldwide creates a substantial demand for effective diagnostic tools. As the global healthcare landscape grapples with the challenges posed by infectious agents, there is a heightened emphasis on developing advanced diagnostic technologies to enable timely and accurate detection.

The key players in this market are Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Siemens Healthineers AG (Germany), Danaher (US), Hologic, Inc. (US), Becton, Dickinson and Company (US), Revvity (US), QIAGEN (Netherlands), Seegene Inc. (South Korea), Grifols, S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), QuidelOrtho Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech (Ireland), Chembio Diagnostics, Inc. (US), Co-Diagnostics, Inc. (US), ELITech Group (France), Epitope Diagnostics, Inc. (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International, Inc. (US), Vela Diagnostics (Singapore), and Uniogen Oy (Finland).

To know about the assumptions considered for the study download the pdf brochure

In 2022, F. Hoffmann-La Roche Ltd. (Switzerland) held a leading position in the infectious disease diagnostics market. The company has maintained this position in the market through its strong distribution networks across North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Roche has a strong direct and indirect distribution network globally, which helps insulate its business from demand fluctuations in various geographies. The company adopts inorganic growth strategies to increase its dominance in this market. The company focuses on strategies, such as partnerships and acquisitions, to garner a larger market share. In November 2021, the company launched cobas 5800 molecular laboratory instruments used for infectious disease diagnostics.

In 2022, Abbott (US) held a significant market share in the infectious disease diagnostics market. Its dominant position in this market can be credited to the robust global sales and distribution network, allowing effective product marketing across diverse countries. Additionally, Abbott has heightened its emphasis on research and development endeavors. The company's substantial investments in R&D, aimed at refining its portfolio and optimizing capital allocation strategies, contribute to its prospective growth and sustained competitiveness in the Diagnostics segment.In addition, Abbott’s strategies, which involve product launches and regulatory approvals, aim to further strengthen its position in the infectious disease diagnostics market. For instance, in March 2021, the company received Emergency Use Authorization (EUA) from the FDA for a laboratory PCR assay, Alinity m Resp-4-Plex molecular assay, that detects and differentiates between SARS-COV-2, flu A, flu B, and RSV in one test.

In 2022, bioMérieux (France) accounted for the third largest share of the infectious disease diagnostics market. The company has successfully positioned itself as a strong player in the infectious disease diagnostics market. The firm focuses on developing innovative products for infectious disease indications. In May 2022, the company received a CE mark for its VIDAS tests for Chikungunya virus diagnosis.

Related Reports:

Infectious Disease Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (Immunodiagnostics, NGS, PCR, ISH, INAAT), Disease (Hepatitis, HIV, HAI, HPV, Syphilis, TB, Flu) - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]